Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Kiniksa Pharmaceuticals International Cash Ratio?
Kiniksa Pharmaceuticals InternationalKNSA 50 Cash Ratio is 3.07 as of Jun. 2026, which is 24% below its 10-year median of 4.06. GuruFocus rates KNSA with a GF Score™ of 50/100 and a GF Value™ of $54.26 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 971 Drug Manufacturers companies, Kiniksa Pharmaceuticals International ranks better than 85.99% on this metric.
Kiniksa Pharmaceuticals International has a Cash Ratio of 3.07. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
Kiniksa Pharmaceuticals International (NAS:KNSA) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Kiniksa Pharmaceuticals International Cash Ratio Related Terms
Kiniksa Pharmaceuticals International Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International Cash Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a Cash Ratio of 3.07 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is 24% below median its historical median of 4.06. Over the past decade, Kiniksa Pharmaceuticals International's Cash Ratio has ranged from 2.33 to 24.31. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #136 out of 971 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Kiniksa Pharmaceuticals International's Cash Ratio too high?
Kiniksa Pharmaceuticals International's current Cash Ratio of 3.07 is 24% below median its 10-year median of 4.06. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 24.31. The Drug Manufacturers industry median Cash Ratio is 0.60. Kiniksa Pharmaceuticals International's value of 3.07 is 411.7% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #136 out of 971 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Cash Ratio compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #136 out of 971 companies for Cash Ratio. This places Kiniksa Pharmaceuticals International in the top 14% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.60. Kiniksa Pharmaceuticals International's value of 3.07 is 411.7% above this benchmark. Historically, Kiniksa Pharmaceuticals International's own Cash Ratio has ranged from 2.33 to 24.31 over the past decade. While the company's 10-year median is 4.06 vs. the industry median of 0.60, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current Cash Ratio of 3.07 is 411.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current Cash Ratio is 3.07, which is 24% below median its own 10-year median of 4.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.26, compared to a current price of $77.80 — trading 43.4% above its estimated fair value. The current Cash Ratio is 3.07, which is 24% below median its 10-year median of 4.06 and 411.7% above the Drug Manufacturers industry median of 0.60. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Cash Ratio is 3.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $77.80 is trading 43.4% above its estimated GF Value™ of $54.26.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
Cash Ratio: 3.07 (24% below median its 10-year median of 4.06)
GF Value™: $54.26 vs. price of $77.80 (43.4% above fair value)
Industry Position: 411.7% above the Drug Manufacturers median (#136 of 971)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score
Get the complete analysis for KNSA
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
